List view / Grid view
The company suggests their experimental COVID-19 vaccine, UB-612, has the features and potential to disrupt the traditional vaccine distribution and supply status quo.
The fourth iteration of the COVID-19 treatment trial will determine whether remdesivir plus baricitinib or dexamethasone is more effective at promoting recovery from COVID-19.
A trial of CT-P59, an anti-COVID-19 monoclonal antibody, has completed its enrolment and will study the treatment against standard-of-care.
Researchers have shown that recipients of the Bacillus Calmette-Guérin (BCG) vaccine are less likely to contract COVID-19 in a new study.
The top considerations for hand sanitiser manufacturers in the UK are outlined in this article by Robert Bussey.
The trial will evaluate if the long-acting monoclonal antibody cocktail, AZD7442, can prevent COVID-19 in patients who cannot be vaccinated.
The Emergency Use Authorization (EUA) is based on a trial in which casirivimab and imdevimab reduced hospitalisations in mild to moderate COVID-19 patients.
Both the UK and US have said that, if approved, the Pfizer and BioNTech COVID-19 vaccine could be administered to people as early as December.
The University of Oxford and AstraZeneca COVID-19 vaccine candidate, ChAdOx1 nCoV-2019, prevented infection from SARS-CoV-2 in two dosing regimens.
The companies suggest if the Emergency Use Authorization (EUA) is approved, high-risk patients in the US could begin receiving the BNT162b2 vaccine by the end of December 2020.
The WHO group concluded there is currently no evidence that remdesivir improves survival when reviewing data from 7000 hospitalised COVID-19 patients.
Report reveals global pharma supply chain leaders are afraid of the vulnerabilities in the end-to-end supply chain as the COVID-19 pandemic continues.
The concluded Phase III study of BNT162b2 met all primary efficacy endpoints, with a consistent 95 percent efficacy across all patient populations.
The DSRU said that global collaboration would be required to successfully expedite the necessary safety and efficacy evaluations for repurposed drugs to be used in COVID-19 patients.
Reports have found that the COVID-19 pandemic is providing new opportunities for contract and development manufacturing organisations (CDMOs).
